mProX™ Human CXCR6 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CXCR6, a chemokine receptor, has been at the forefront of numerous scientific investigations due to its multifaceted roles in various physiological and pathological processes. One of the significant findings is its role in liver pathology, particularly in nonalcoholic steatohepatitis (NASH). Research has shown that liver resident CD8 T cells, which express CXCR6, play a pivotal role in the immunopathology of NASH. Furthermore, CXCR6 has been identified as a key player in the tumor microenvironment. It has been revealed that the upregulation of CXCR6 positions cytotoxic T cells in such a way that it determines the magnitude and outcome of anti-tumor immune responses. Another intriguing discovery is the association of CXCR6 with Th17 cells, which are known to have cytotoxic properties, especially in the context of Experimental Autoimmune Encephalomyelitis (EAE). In the realm of tumor immunotherapy, CXCR6 has been proposed as a potential biomarker for effective CD8+ T cell states before adoptive cell therapy. In summary, CXCR6 is emerging as a pivotal molecule in various research areas, from liver diseases to tumor immunology, making it a promising target for future therapeutic interventions.